How drugs like Ozempic are messing with people’s smell and taste
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"How drugs like Ozempic are messing with people’s smell and taste" is generating significant coverage in the Health category, with 1 articles from 1 distinct sources tracked by PULSE so far.
Outlets currently covering the story include CTV News. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 107d ago.
Quick answers
Why is "How drugs like Ozempic are messing with people’s smell and taste" trending?
Because 1 independent news sources published 1 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (1)
- GLP-1s linked to smell and taste impairment in diabetes patients CTV News · 145d ago
Topics
Related trends
Ozempic and Mounjaro may have a surprising effect on your brain
Coverage from five outlets reports that Ozempic and Mounjaro may affect memory and brain function, with evidence described as mixed.
Should you take GLP-1s during pregnancy? What some doctors say.
New research on GLP-1 drugs during pregnancy sparks urgent debate among doctors and patients.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
How Nvidia's scandal knocked thousands off your 401(k)
Nvidia shares have fallen roughly one-third from an October peak after CEO Jensen Huang's reported resignation, rippling through retirement accounts and sparking debate over equal-weight versus cap-weighted fund exposure.
Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.
College Football Playoff format for 24-team field: How rankings would look in 2026
College football is moving toward a 24-team playoff, prompting coaches and analysts to question the future of conference championship games and the sport's traditional structure.